Myoguide poised to become essential pain and spasticity treatment tool in hands of European physicians
Bolton, Ontario, June 16, 2011- Clinicians throughout the European Union may now treat their patients suffering from acute and chronic pain or spasticity with a highly portable electromyographic (EMG) precision device from Intronix Technologies Corp. in Canada that can help target and treat unseen sources of pain with unprecedented precision.
The newly approved Myoguide battery-powered handheld provides superior injection site targeting through its ability to detect and display the EMG signals characteristically emitted by these hidden pain sources.
Intronix officials will demonstrate the latest version of Myoguide, also featuring new software and other improvements, at MEDICA 2011, the world’s largest annual medical trade fair, November 16-19 in Düsseldorf, Germany. Intronix will be exhibiting in Hall 16 as part of the Ontario, Canada pavilion.
“We’ve had Myoguide on display at previous MEDICAs, but we are extremely pleased to be coming back with our new version, proudly bearing its CE mark,” says Dr. Evan Friedman, CEO and co-founder of Intronix Technologies. “Myoguide is already in use in other countries and we have a line-up of clients in the United States awaiting Myoguide’s FDA approval. But now our distributors, both current and new, can really get to work in Europe.”
According to clinical studies, use of Myoguide can lead to more accurate injection site targeting, which may also enhance treatment of pain and spasticity, and improve the outcomes of treatment.
“Myoguide quickly becomes an essential tool because it makes finding these sites straightforward. Clinicians using it can see and hear the pain-related EMG activity” says Friedman. “Myoguide provides both quantitative and qualitative feedback necessary for clinicians to make decisions about treatment and treatment delivery.”
Treatment delivery can be in the form of neuromodulator injections, such as Botox©, Dysport©, and Xeomin©, or as simple as inserting a dry needle electrode.
About Intronix Technologies:
Intronix, a Canadian company, has been manufacturing medical devices since 1984, and for other companies, as an original equipment manufacturer (OEM), since 1989. Intronix designs and produces innovative EMG systems for applications in the diagnosis and management of pain, spasticity, and ﬁbromyalgia. For more information, visit http://www.intronixtech.com for a wealth of information on Myoguide, including clinical video demonstrations.
Intronix Technologies Corporation email@example.com